Geriatric psychopharmacology: Why does age matter?

Harvard Review of Psychiatry

Volumn 7, Issue 6, 2000, Pages 311-333

  Zubenko, George S ^a,b,d   Sunderland, Trey ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Carnegie Mellon University   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BUSPIRONE; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CLOZAPINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PERPHENAZINE; PSYCHOTROPIC AGENT; RISPERIDONE; SELEGILINE; SERTINDOLE; SERTRALINE; THIORIDAZINE; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE;

AGED; AGING; BEHAVIOR DISORDER; COMORBIDITY; DEGENERATIVE DISEASE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE; DRUG EFFECT; HUMAN; PATIENT COMPLIANCE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW;

EID: 0034065329     PISSN: 10673229     EISSN: None     Source Type: Journal    
DOI: 10.3109/hrp.7.6.311     Document Type: Review

References (202)

1. Popkin MK, Callies AL, Mackenzie TB. The outcome of antidepressant use in the medically ill. Arch Gen Psychiatry 1985;42:1160-3.
2. Katz IR, Simpson GM, Curlik SM, Parmelee PA, Muhly C. Pharmacologic treatment of major depression for elderly patients in residential care settings. J Clin Psychiatry 1990; 51(suppl):41-7.
3. Zubenko GS, Mulsant BH, Rifai AH, Sweet RA, Pasternak RE, Marino LJ Jr, et al. Impact of acute psychiatric inpatient treatment on major depression in late life and prediction of response. Am J Psychiatry 1994;151:987-94.
4. Baum C, Kennedy DL, Knapp DE, Juergens JP, Faich GA. Prescription drug use in 1984 and changes over time. Med Care 1988;26:105-14.
5. Chrischilles EA, Foley DJ, Wallace RB, Lemke JH, Semla TP, Hanlon JT, et al. Use of medications by persons 65 and over: data from the established populations for epidemiologic studies of the elderly. J Gerontol Med Sci 1992;47:M137-44.
6. Helling DK, Lemke JH, Semla TP, Wallace RB, Lipson DP, Cornoni-Huntley J. Medication use characteristics in the elderly: the Iowa 65+ Rural Health Study. J Am Geriatr Soc 1987;35:4-12.
7. Lamy PP. Prescribing for the elderly. Littleton, Massachusetts: PSG, 1980.
8. Zubenko GS, Marino LJ Jr, Sweet RA, Rifai AH, Mulsant BH, Pasternak RE. Medical comorbidity in elderly psychiatric inpatients. Biol Psychiatry 1997;41:724-36.
9. Sonies BC. Oropharyngeal dysphagia in the elderly. Clin Geriatr Med 1992;8:569-77.
10. Jost WH. Gastrointestinal motility problems in patients with Parkinson's disease: effects of antiparkinsonian treatment and guidelines for management. Drugs Aging 1997;10: 249-58.
11. Ribeiro AC, Klingler PJ, Hinder RA, DeVault K. Esophageal manometry: a comparison of findings in younger and older patients. Am J Gastroenterol 1998;93:706-10.
12. Schmucker DL. Aging and drug disposition: an update. Pharmacol Rev 1985;37:133-48.
13. Annesley TM. Special considerations for geriatric therapeutic drug monitoring. Clin Chem 1989;35:1337-41.
14. Altman, DF. Changes in gastrointestinal, pancreatic, biliary, and hepatic function with aging. Gastroenterol Clin North Am 1990;19:227-34.
15. Russell RM. Changes in gastrointestinal function attributed to aging. Am J Clin Nutr 1992;55(6, suppl):1203-7S.
16. Pilotto A, Franceschi M, Del Favero G, Fabrello R, Di Mario F, Valerio G. The effect of aging on oro-cecal transit time in normal subjects and patients with gallstone disease. Aging (Milano) 1995;7:234-7.
17. Trey G, Marks IN, Louw JA, Jaskiewicz K, Sipponen P, Novis BH, et al. Changes in acid secretion over the years: a 30-year longitudinal study. J Clin Gastroenterol 1997;25:499-502.
18. Holt PR, Balint JA. Effects of aging on intestinal lipid absorption. Am J Physiol 1993;264:G1-6.
19. Forbes GB, Reina JC. Adult lean body mass declines with age: some longitudinal observations. Metabolism 1970;19: 653-63.
20. Novak LP. Aging, total body potassium, fat-free mass, and cell mass in males and females between ages 18 and 85 years. J Gerontol 1972;27:438-43.
21. Borkan GA, Hults DE, Gerzof SG, Robbins AH, Silbert CK. Age changes in body composition revealed by computed tomography. J Gerontol 1983;38:673-7.
22. Kleine TO, Hackler R. Age-related changes in the blood-brain barrier of humans. Neurobiol Aging 1994;15:763-4.
23. Kalaria RN. Cerebral vessels in ageing and Alzheimer's disease. Pharmacol Ther 1996;72:193-214.
24. Shah GN, Mooradian AD. Age-related changes in the blood-brain barrier. Exp Gerontol 1997;32:501-19.
25. Skoog I, Wallin A, Fredman P, Hesse C, Aevarsson O, Karlsson I, et al. A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology 1998;50:966-71.
26. Loi CM, Vestal RE. Drug metabolism in the elderly. Pharmacol Ther 1988;36:131-49.
27. Greenblatt DJ. Reduced serum albumin concentration in the elderly: a report from the Boston Collaborative Drug Surveillance Program. J Am Geriatr Soc 1979;27:20-2.
28. Adir J, Miller AK, Vestal RE. Effects of total plasma concentration and age on tolbutamide plasma protein binding. Clin Pharmacol Ther 1982;31:488-93.
29. Abernethy DR, Kerzner L. Age effects on alpha-1-acid glycoprotein concentration and imipramine plasma protein binding. J Am Geriatr Soc 1984;32:705-8.
30. 1-glycoprotein. Ther Drug Monit 1993;15:267-73.
31. rd ed. Baltimore: Williams & Wilkins, 1998:70-93.
32. Woodhouse KW, James OFW. Hepatic drug metabolism and ageing. Br Med Bull 1990;46:22-35.
33. Yuen GJ. Altered pharmacokinetics in the elderly. Clin Geriatr Med 1990;6:257-67.
34. Le Couteur DG, McLean AJ. The aging liver: drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998;34:359-73.
35. Schmucker DL, Woodhouse KW, Wang RK, Wynne H, James OF, McManus M, et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 1990;48:365-74.
36. Hunt CM, Westerkam WR, Stave GM, Wilson JAP. Hepatic cytochrome P-4503A (CYP3A) activity in the elderly. Mech Ageing Dev 1992;64;189-99.
37. Pollock BG, Perel JM, Altieri LP, Kirshner M, Fasiczka AL, Houck PR, et al. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol Bull 1992; 28:163-8.
38. Pollock BG. Recent developments in drug metabolism of relevance to psychiatrists. Harvard Rev Psychiatry 1994;2: 204-13.
39. Gelenberg AJ. The P450 family. Biol Ther Psychiatry Newsl 1995;18:29-31.
40. Nemeroff CB, Devane CL, Pollack BG. Summary and review of antidepressants and the cytochrome P450 system. Am Soc Clin Psychopharmacol Progress Notes 1995-96;6(4):38-40.
41. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-20.
42. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84-112.
43. Patel J, Salzman C. Enzyme metabolism and drug interaction. In: Salzman C, ed. Clinical geriatric psychopharmacology. 3rd ed. Baltimore: Williams & Wilkins, 1998: 547-52.
44. Anonymous. Reference guide to substrates, inhibitors and inducers of the major human liver cytochrome P450 enzymes involved in xenobiotic transformation. Research Triangle Park, North Carolina: Intek Labs, 1999.
45. Anonymous. Micromedex computer and clinical information system, vol 99. Englewood, Colorado: Micromedex, 1999.
46. Schmucker DL. Age-related changes in drug disposition. Pharmacol Rev 1978;30:445-56.
47. Pearson MW, Roberts CJC. Drug induction of hepatic enzymes in the elderly. Age Ageing 1984;13:313-6.
48. Vestal RE. Aging and determinants of hepatic drug clearance. Hepatology 1989;9:331-4.
49. Zubenko GS. Molecular neurobiology of Alzheimer's disease (syndrome?). Harvard Rev Psychiatry 1997;5:177-213.
50. Baum C, Kennedy DL, Knapp DE, Faich GA. Drug utilization in the US: 1985. Seventh Annual Review, Food and Drug Administration, Center for Drugs and Biologics, Rockville, Maryland, 1986.
51. Balter MB, Levine J, Manheimer DI. Cross-national study of the extent of anti-anxiety sedative drug use. N Engl J Med 1974;290:769-74.
52. Boston Collaborative Drug Surveillance Program. Clinical depression of the central nervous system due to diazepam and chlordiazepoxide in relation to cigarette smoking and age. N Engl J Med 1973;288:277-80.
53. Castleden CM, George CF, Marcer D, Hallett C. Increased sensitivity to nitrazepam in old age. BMJ 1977;1:10-2.
54. Giles HG, MacLeod SM, Wright JR, Sellers EM. Influence of age and previous use on diazepam dosage required for endoscopy. Can Med Assoc J 1978;118:513-4.
55. Reidenberg MM, Levy M, Warner H, Coutinho CB, Schwartz MA, Yu G, et al. Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clin Pharmacol Ther 1978;23:371-4.
56. Thompson TL II, Moran MG, Nies AS. Psychotropic drug use in the elderly: part 1. N Engl J Med 1983;308:134-8.
57. Thompson TL II, Moran MG, Nies AS. Psychotropic drug use in the elderly: part 2. N Engl J Med 1983;308:194-9.
58. Cook PJ, Flanagan R, James IM. Diazepam tolerance: effect of age, regular sedation, and alcohol. BMJ 1984;289:351-3.
59. Pomara N, Stanley B, Block R, Guido J, Russ D, Berchou R, et al. Adverse effects of single therapeutic doses of diazepam on performance in normal geriatric subjects: relationship to plasma concentrations. Psychopharmacology 1984;84: 342-6.
60. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989;262:3303-7.
61. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations (part II). Clin Pharmacokinet 1991; 21:262-73.
62. Kroboth PD, McAuley JW, Smith RB. Alprazolam in the elderly: pharmacokinetics and pharmacodynamics during multiple dosing. Psychopharmacology 1990;100:477-84.
63. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations (part I). Clin Pharmacokinet 1991;21: 165-77.
64. Herings RMC, Stricker BH, De Boer A, Bakker A, Sturmans F. Benzodiazepines and the risk of falling leading to femur fractures: dosage more important than elimination half-life. Arch Intern Med 1995;155:1801-7.
65. Pomara N, Stanley B, Block R, Berchou RC, Stanley M, Greenblatt DJ, et al. Increased sensitivity of the elderly to the central depressant effects of diazepam. J Clin Psychiatry 1985;46:185-7.
66. Swift CG, Ewen JM, Clarke P, Stevenson IH. Responsiveness to oral diazepam in the elderly: relationship to total and free plasma concentrations. Br J Clin Pharmacol 1985;20:111-8.
67. Nikaido AM, Ellinwood EH Jr, Heatherly DG, Gupta SK. Age-related increase in CNS sensitivity to benzodiazepines as assessed by task difficulty. Psychopharmacology 1990; 100:90-7.
68. Bertz RJ, Kroboth PD, Kroboth FJ, Reynolds IJ, Salek F, Wright CE, et al. Alprazolam in young and elderly men: sensitivity and tolerance to psychomotor, sedative and memory effects. J Pharmacol Exp Ther 1997;281:1317-29.
69. Allen SJ, Benton JS, Goodhardt MJ, Haan EA, Sims NR, Smith CC, et al. Biochemical evidence of selective nerve cell changes in the normal ageing human and rat brain. J Neurochem 1983;41:256-65.
70. McGeer EG. Neurotransmitter system in aging and senile dementia. Prog Neuropsychopharmacol 1981;5:435-45.
71. Bareggi SR, Franceschi M, Smirne S. Neurochemical findings in cerebrospinal fluid in Alzheimer's disease. In: Gottfries CG, ed. Normal aging, Alzheimer's disease, and senile dementia: aspects of etiology, pathogenesis, diagnosis, and treatment. Brussels: Éditions de l'Université de Bruxelles, 1985:203-12.
72. Hare TA, Wood JH, Manyam BV, Gerner RH, Ballenger JC, Post RM. Central nervous system γ-aminobutyric acid activity in man; relationship to age and sex as reflected in CSF. Arch Neurol 1982;39:247-9.
73. Satlin A, Liptzin B. Diagnosis and treatment of mania. In: Salzman C, ed. Clinical geriatric psychopharmacology. 3rd ed. Baltimore: Williams & Wilkins, 1998:310-30.
74. Tune L, Carr S, Hoag E, Cooper T. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992;149: 1393-4.
75. Molchan SE, Martinez RA, Hill JL, Weingartner HJ, Thompson K, Vitiello B, et al. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev 1992;17:215-26.
76. 11C]tropanyl benzilate. J Cereb Blood Flow Metab 1996; 16:303-10.
77. Suhara T, Inoue O, Kobayashi K, Suzuki K, Tateno Y. Age-related changes in human muscarinic acetylcholine receptors measured by positron emission tomography. Neurosci Lett 1993;149:225-8.
78. Nordberg A, Alafuzoff I, Winblad B. Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J Neurosci Res 1992;31:103-11.
79. 3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal. J Neurochem 1986;47: 1948-54.
80. m GTPase activity in aging and Alzheimer's disease: implications for altered signal transduction. Brain Res 1994;664: 54-60.
81. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987;76:465-79.
82. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989;262:2551-6.
83. Bachman DL, Wolf PA, Linn R, Knoefel JE, Cobb J, Belanger A, et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 1992;42:115-9.
84. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215:1237-9.
85. Arendt T, Bigl V, Arendt A, Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans, and Korsakoff's disease. Acta Neuropathol (Berl) 1983;61:101-8.
86. Saper CB, German DC, White CL III. Neuronal pathology in the nucleus basalis and associated cell groups in senile dementia of the Alzheimer's type: possible role in cell loss. Neurology 1985;35:1089-95.
87. Pope A, Hess HH, Lewin E. Microchemical pathology of the cerebral cortex in pre-senile dementias. Trans Am Neurol Assoc 1964;89:15-6.
88. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease [Letter]. Lancet 1976;2:1403.
89. Rossor MN, Garrett NJ, Johnson AL, Mountjoy CQ, Roth M, Iversen LL. A post-mortem study of the cholinergic and GABA systems in senile dementia. Brain 1982;105:313-30.
90. Bird TD, Stranahan S, Sumi SM, Raskind M. Alzheimer's disease: choline acetyltransferase activity in brain tissue from clinical and pathological subgroups. Ann Neurol 1983; 14:284-93.
91. Bowen DM, Allen SJ, Benton JS, Goodhardt MJ, Haan EA, Palmer AM, et al. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J Neurochem 1983;41:266-72.
92. Sims NR, Bowen DM, Allen SJ, Smith CCT, Neary D, Thomas DJ, et al. Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem 1983;40:503-9.
93. Drachman DA, Leavitt J. Human memory and the cholinergic system: a relationship to aging? Arch Neurol 1974;30: 113-21.
94. Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217:408-14.
95. Greenamyre JT, Maragos WF. Neurotransmitter receptors in Alzheimer disease. Cerebrovasc Brain Metab Rev 1993;5: 61-94.
96. Smith CJ, Perry EK, Perry RH, Fairbairn AF, Birdsall NJM. Guanine nucleotide modulation of muscarinic cholinergic receptor binding in postmortem human brain - a preliminary study in Alzheimer's disease. Neurosci Lett 1987;82:227-32.
97. 1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies. Ann Neurol 1991;29:256-62.
98. Sunderland T, Esposito G, Molchan SE, Coppola R, Jones DW, Gorey J, et al. Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: a SPECT study. Psychopharmacology 1995;121:231-41.
99. 3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal. J Neurochem 1986;47:1948-54.
100. Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia. J Neurochem 1986;46:288-93.
101. Whitehouse PJ, Martino AM, Antuono PG, Lowenstein PR, Coyle JT, Price DL, et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res 1986;371:146-51.
102. Perry EK, Perry RH, Smith CJ, Dick DJ, Candy JM, Edwardson JA, et al. Nicotinic receptor abnormalities in Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry 1987;50:806-9.
103. Araujo DM, Lapchak PA, Robitaille Y, Gauthier S, Quirion R. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J Neurochem 1988;50:1914-23.
104. Rinne JO, Myllykylä P, Lönnberg P, Marjamäki P. A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Res 1991;547:167-70.
105. Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990;40:1-8.
106. Lippa CF, Smith TW, Swearer JM. Alzheimer's disease and Lewy body disease: a comparative clinicopathological study. Ann Neurol 1994;35:81-8.
107. Perry EK, Marshall E, Perry RH, Irving D, Smith CJ, Blessed G, et al. Cholinergic and dopaminergic activities in senile dementia of Lewy body type. Alzheimer Dis Assoc Disord 1990;4:87-95.
108. Perry EK, McKeith I, Thompson P, Marshall E, Kerwin J, Jabeen S, et al. Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Ann NY Acad Sci 1991;640:197-202.
109. Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 1993;7:69-79.
110. Forstl H, Burns A, Luthert P, Cairns N, Levy R. The Lewy-body variant of Alzheimer's disease: clinical and pathological findings. Br J Psychiatry 1993;162:385-92.
111. Langlais PJ, Thal L, Hansen L, Galasko D, Alford M, Masliah E. Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology 1993;43:1927-34.
112. Kalish SC, Bohn RL, Mogun H, Glynn RJ, Gurwitz JH, Avorn J. Antipsychotic prescribing patterns and the treatment of extrapyramidal symptoms in older people. J Am Geriatr Soc 1995;43:967-73.
113. Sweet RA, Mulsant BH, Gupta B, Rifai AH, Pasternak RE, McEachran A, et al. Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life. Arch Gen Psychiatry 1995;52:478-86.
114. Hartikainen P, Soininen H, Reinikainen KJ, Sirviö J, Soikkeli R, Riekkinen PJ. Neurotransmitter markers in the cerebrospinal fluid of normal subjects: effects of aging and other confounding factors. J Neural Transm Gen Sect 1991;84: 103-17.
115. Zubenko GS, Moossy J, Kopp U. Neurochemical correlates of major depression in primary dementia. Arch Neurol 1990; 47:209-14.
116. Zubenko GS, Moossy J. Major depression in primary dementia: clinical and neuropathologic correlates. Arch Neurol 1988;45:1182-6.
117. Zubenko GS, Moossy J, Martinez AJ, Rao G, Claassen D, Rosen J, et al. Neuropathological and neurochemical correlates of psychosis in primary dementia. Arch Neurol 1991;48: 619-24.
118. Zubenko GS. Clinicopathological and neurochemical correlates of major depression and psychosis in primary dementia. Int Psychogeriatr 1996;8(suppl 3):219-23.
119. Meek JL, Bertilsson L, Cheney DL, Zsilla G, Costa E. Aging-induced changes in acetylcholine and serotonin content of discrete brain nuclei. J Gerontol 1977;32:129-31.
120. Patel A, Maloney A, Damato AN. On the frequency and reproducibility of orthostatic blood pressure changes in healthy community-dwelling elderly during 60-degree head-up tilt. Am Heart J 1993;126:184-8.
121. Mets TF. Drug-induced orthostatic hypotension in older patients. Drugs Aging 1995;6:219-28.
122. Verhaeverbeke I, Mets T. Drug-induced orthostatic hypotension in the elderly: avoiding its onset. Drug Saf 1997;17: 105-18.
123. Abernethy DR. Altered pharmacodynamics of cardiovascular drugs and their relation to altered pharmacokinetics in elderly patients. Clin Geriatr Med 1990;6:285-92.
124. Feely J, Coakley D. Altered pharmacodynamics in the elderly. Clin Geriatr Med 1990;6:269-83.
125. Hämmerlein A, Derendorf H, Lowenthal DT. Pharmocokinetic and pharmacodynamic changes in the elderly: clinical implications. Clin Pharmacokinet 1998;35:49-64.
126. Cumming RG. Epidemiology of medication-related falls and fractures in the elderly. Drugs Aging 1998;12:43-53.
127. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med 1988;319:1701-7.
128. Campbell AJ, Borrie MJ, Spears GF. Risk factors for falls in a community-based prospective study of people 70 years and older. J Gerontol Med Sci 1989;44:M112-7.
129. Campbell AJ, Borrie MJ, Spears GF, Jackson SL, Brown JS, Fitzgerald JL. Circumstances and consequences of falls experienced by a community population 70 years and over during a prospective study. Age Ageing 1990;19:136-41.
130. Tinetti ME, Speechley M. Prevention of falls among the elderly. N Engl J Med 1989;320:1055-9.
131. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1985;7:178-208.
132. Katelaris AG, Cumming RG. Health status before and mortality after hip fracture. Am J Public Health 1996;86:557-60.
133. Cumming RG, Klineberg R, Katelaris A. Cohort study of risk of institutionalisation after hip fracture. Aust NZ J Public Health 1996;20:579-82.
134. Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ III. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987;316:363-9.
135. Ray WA, Griffin MR, Malcolm E. Cyclic antidepressants and the risk of hip fracture. Arch Intern Med 1991;151:754-6.
136. Lipsitz LA, Jonsson PV, Kelley MM, Koestner JS. Causes and correlates of recurrent falls in ambulatory frail elderly. J Gerontol Med Sci 1991;46:M114-22.
137. Ruthazer R, Lipsitz LA. Antidepressants and falls among elderly people in long-term care. Am J Public Health 1993;83: 746-9.
138. Sorock GS, Shimkin EE. Benzodiazepine sedatives and the risk of falling in a community dwelling elderly cohort. Arch Intern Med 1988;148:2441-4.
139. Cumming RG, Miller JP, Kelsey JL, Davis P, Arfken CL, Birge SJ, et al. Medications and multiple falls in elderly people: the St. Louis OASIS study. Age Ageing 1991;20: 455-61.
140. Aisen PS, Deluca T, Lawlor BA. Falls among geropsychiatry inpatients are associated with PRN medications for agitation. Int J Geriatr Psychiatry 1992;7:709-12.
141. Cumming RG, Klineberg RJ. Psychotropics, thiazide diuretics and hip fractures in the elderly. Med J Aust 1993;158: 414-7.
142. Ryynänen OP, Kivelä SL, Honkanen R, Laippala P, Saano V. Medications and chronic diseases as risk factors for falling injuries in the elderly. Scand J Soc Med 1993;21:264-71.
143. Yip YB, Cumming RG. The association between medications and falls in Australian nursing-home residents. Med J Aust 1994;160:14-8.
144. Gales BJ, Menard SM. Relationship between the administration of selected medications and falls in hospitalized elderly patients. Ann Pharmacother 1995;29:354-8.
145. Lord SR, Anstey KJ, Williams P, Ward JA. Psychoactive medication use, sensori-motor function and falls in older women. Br J Clin Pharmacol 1995;39:227-34.
146. Luukinen H, Koski K, Laippala P, Kivelä SL. Predictors for recurrent falls among the home-dwelling elderly. Scand J Prim Health Care 1995;13:294-9.
147. Prudham D, Evans JG. Factors associated with falls in the elderly: a community study. Age Ageing 1981;10:141-6.
148. Sorock GS. A case-control study of falling incidents among the hospitalized elderly. J Saf Res 1983;14:47-52.
149. Mion LC, Gregor S, Buettner M, Chwirchak D, Lee O, Paras W. Falls in the rehabilitation setting: incidence and characteristics. Rehab Nurs 1989;14:17-22.
150. Wells BG, Middleton B, Lawrence G, Lillard D, Safarik J. Factors associated with the elderly falling in intermediate care facilities. Drug Intell Clin Pharm 1985;19:142-5.
151. Lord SR, Sambrook PN, Gilbert C, Kelly PJ, Nguyen T, Webster IW, et al. Postural stability, falls and fractures in the elderly: results from the Dubbo Osteoporosis Epidemiology Study. Med J Aust 1994;160:684-5, 688-91.
152. Ensrud KE, Nevitt MC, Yunis C, Hulley SB, Grimm RH, Cummings SR. Postural hypotension and postural dizziness in elderly women: the study of osteoporotic fractures. Arch Intern Med 1992;152:1058-64.
153. Koski K, Luukinen H, Laippala P, Kivelä SL. Physiological factors and medications as predictors of injurious falls by elderly people: a prospective population-based study. Age Ageing 1996;25:29-38.
154. Middler S, Pak CY, Murad F, Bartter FC. Thiazide diuretics and calcium metabolism. Metabolism 1973;22:139-46.
155. Jones G, Nguyen T, Sambrook PN, Eisman JA. Thiazide diuretics and fractures: can meta-analysis help? J Bone Miner Res 1995;10:106-11.
156. Lipsitz LA, Jonsson PV, Kelley MM, Koestner JS. Causes and correlates of recurrent falls in ambulatory frail elderly. J Gerontol Med Sci 1991;46:M114-22.
157. Myers AH, Baker SP, Van Natta ML, Abbey H, Robinson EG. Risk factors associated with falls and injuries among elderly institutionalized persons. Am J Epidemiol 1991;133: 1179-90.
158. Hoppmann RA, Peden JG, Ober SK. Central nervous system side effects of nonsteroidal anti-inflammatory drugs: aseptic meningitis, psychosis, and cognitive dysfunction. Arch Intern Med 1991;151:1309-13.
159. Bauer DC, Orwoll ES, Fox KM, Vogt TM, Lane NE, Hochberg MC, et al. Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. J Bone Miner Res 1996;11:29-35.
160. Shorr RI, Griffin MR, Daugherty JR, Ray WA. Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene. J Gerontol Med Sci 1992;47:M111-5.
161. Robbins AS, Rubenstein LZ, Josephson KR, Schulman BL, Osterweil D, Fine G. Predictors of falls among elderly people: results of two population-based studies. Arch Intern Med 1989;149:1628-33.
162. Thapa PB, Gideon P, Fought RL, Ray WA. Psychotropic drugs and risk of recurrent falls in ambulatory nursing home residents. Am J Epidemiol 1995;142:202-11.
163. Cooper JK, Love DW, Raffoul PR. Intentional prescription nonadherence (noncompliance) by the elderly. J Am Geriatr Soc 1982;30:329-33.
164. Ostrom JR, Hammarlund ER, Christensen DB, Plein JB, Kethley AJ. Medication usage in an elderly population. Med Care 1985;23:157-64.
165. Jackson JE, Ramsdell JW, Renvall M, Swart J, Ward H. Reliability of drug histories in a specialized geriatric outpatient clinic. J Gen Intern Med 1989;4:39-43.
166. nd ed. Baltimore: Williams & Wilkins, 1992:15-37.
167. Lamy PP. Compliance in long-term care. Geriatr Med Today 1986;5:61-75.
168. Col N, Fanale JE, Kronholm P. The role of medication non-compliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med 1990;150:841-5.
169. Mesulam MM, Mufson EJ, Rogers J. Age-related shrinkage of cortically projecting cholinergic neurons: a selective effect. Ann Neurol 1987;22:31-36.
170. Cohen BM, Renshaw PF, Stoll AL, Wurtman RJ, Yurgelun-Todd D, Babb SM. Decreased brain choline uptake in older adults: an in vitro proton magnetic resonance spectroscopy study. JAMA 1995;274:902-7.
171. Court JA, Perry EK, Johnson M, Piggott MA, Kerwin JA, Perry RH, et al. Regional patterns of cholinergic and glutamate activity in the developing and aging human brain. Brain Res Dev Brain Res 1993;74:73-82.
172. Allen SJ, Benton JS, Goodhardt MJ, Haan EA, Sims NR, Smith CC, et al. Biochemical evidence of selective nerve cell changes in the normal ageing human and rat brain. J Neurochem 1983;41:256-65.
173. Nakano S, Kato T, Nakamura S, Kameyama M. Acetylcholinesterase activity in cerebrospinal fluid of patients with Alzheimer's disease and senile dementia. J Neurol Sci 1986;75: 213-23.
174. Morgan DG, May PC, Finch CE. Dopamine and serotonin systems in human and rodent brain: effects of age and neurodegenerative disease. J Am Geriatr Soc 1987;35:334-45.
175. McGeer EG. Neurotransmitter systems in aging and senile dementia. Prog Neuropsychopharmacol 1981;5:435-45.
176. Robinson DS, Sourkes TL, Nies A, Harris LS, Spector S, Bartlett DL, et al. Monoamine metabolism in human brain. Arch Gen Psychiatry 1977;34:89-92.
177. Oreland L, Gottfries CG. Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type. Prog Neuropsychopharmacol Biol Psychiatry 1986;10:533-40.
178. De Keyser J, Ebinger G, Vauquelin G. Age-related changes in the human nigrostriatal dopaminergic system. Ann Neurol 1990;27:157-161.
179. Volkow ND, Wang GJ, Fowler JS, Ding YS, Gur RC, Gatley J, et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann Neurol 1998;44:143-7.
180. 11C] raclopride. J Cereb Blood Flow Metab 1993;13:310-4.
181. 2 receptor availability in healthy human subjects. Life Sci 1995;56:PL249-53.
182. Roth GS, Joseph JA. Age-related changes in the transcriptional and posttranscriptional regulation of the dopaminergic system. Life Sci 1994;55:2031-5.
183. Van Dyck CH, Seibyl JP, Malison RT, Lamelle M, Wallace E, Zoghbi SS, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CIT SPECT. J Nucl Med 1995;36:1175-81.
184. Volkow ND, Fowler JS, Wang GJ, Logan J, Schlyer D, MacGregor R, et al. Decreased dopamine transporters with age in healthy human subjects. Ann Neurol 1994;36:237-9.
185. Bannon MJ, Poosch MS, Xia Y, Goebel DJ, Cassin B, Kaspatos G. Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age. Proc Natl Acad Sci USA 1992;89:7095-9.
186. Mann DMA. Is the pattern of nerve cell loss in aging and Alzheimer's disease a real, or only an apparent, selectivity? Neurobiol Aging 1991;12:340-3.
187. i proteins in the human brain: ratio of high-affinity agonist sites to antagonist sites and effect of age. J Pharmacol Exp Ther 1994;269:1062-72.
188. 2-adrenergic receptor density is decreased in older humans. J Gerontol Biol Sci 1993;48:B173-9.
189. 2-adrenoceptors in the human brain. Brain Res 1992;585: 116-27.
190. 3H]p-aminoclonidine binding in prefrontal cortex. Neurobiol Aging 1991;12:131-6.
191. 2 and β-adrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatry 1990;47:1038-47.
192. 2-receptors in prefrontal cortex and hippocampus. J Neurochem 1989;53:1772-81.
193. Insel PA. Adrenergic receptors, G proteins, and cell regulation: implications for aging research. Exp Gerontol 1993;28: 341-8.
194. Gottfries CG. Neurochemical aspects of aging and diseases with cognitive impairment. J Neurosci Res 1990;27:541-7.
195. Marcusson J, Oreland L, Winblad B. Effect of age on human brain serotonin (S-1) binding sites. J Neurochem 1984;43: 1699-705.
196. 2A receptor mRNAs in human hippocampus using a reverse transcriptase-polymerase chain reaction (RT-PCR) technique and their correlation with binding site densities and age. Neurosci Lett 1994;178:85-9.
197. 3H]imipramine binding of protein nature in the human brain, II: Effect of normal aging and dementia disorders. Brain Res 1987;425:137-45.
198. Middlemiss DN, Palmer AM, Edel N, Bowen DM. Binding of the novel serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin in normal and Alzheimer brain. J Neurochem 1986; 46:993-6.
199. 2A receptors: influence of age and gender in healthy subjects. Eur J Nucl Med 1998;25: 1617-22.
200. 18F] altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. Brain Res 1998;813:167-71.
201. 2 receptor availability in healthy human subjects. Life Sci 1995;56:PL249-53.
202. Sparks DL. Aging and Alzheimer's disease: altered cortical serotonergic binding. Arch Neurol 1989;46:138-40.